Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers

This study has been terminated.
Sponsor:
Information provided by:
PhotoCure
ClinicalTrials.gov Identifier:
NCT00496171
First received: July 3, 2007
Last updated: January 15, 2009
Last verified: January 2009

July 3, 2007
January 15, 2009
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00496171 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase I Study of HAL Formulations Applied to the Cervix in Healthy Volunteers
A Phase I Hexaminolevulinate (HAL) Dose-Finding Study Applying Different Formulations to the Cervix in Healthy Volunteers

The purpose of the study is to determine the most effective formulation of HAL for release of hexaminolevulinate to the cervical epithelium at different doses.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Healthy
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Healthy, pre-menopausal female volunteers

Exclusion Criteria:

  • Acute or chronic disease which could influence the study results
Female
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00496171
PC CE102/07
Not Provided
Not Provided
PhotoCure
Not Provided
Principal Investigator: Claes G Tropé, MD PhD Riks-Radium University Hospital
PhotoCure
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP